WE@HealthTech
Gull Ben-David currently serves as Technology Manager at OrganoSpheres Consortium, overseeing a collaborative effort among technology companies, academia, pharmaceuticals, and CROs to enhance the scientific infrastructure aimed at drug research and development. Gull also holds a membership at WE@HealthTech since May 2023. Previously, Gull excelled as Director of Product Management at CytoReason from January 2021 to August 2023, contributing significantly in various product-related roles. Prior experience at MyHeritage involved managing the purchase funnel and billing system, where Gull joined the product management team at its inception and led initiatives for continuous integration as a QA Engineer. Earlier military service as a Helicopter Flight Instructor focused on training CH-53 and Blackhawk pilots using a virtual reality simulator. Gull holds a Master’s degree in Literature from Tel Aviv University and a Bachelor of Arts in Biology from The Hebrew University of Jerusalem.
This person is not in the org chart
WE@HealthTech
Women comprise about 70% of the HealthTech industry work force. Out of the 30 companies listed in the Biomed Index there are only two women CEOs amongst a total of sixty CEOs and Chairmen. The share value of companies that include women on their boards are higher by an average of 44% (Goldman Sachs). FORTUNE 500 companies with a larger number of women in senior management positions have better financial results (Catalyst). It follows that proper representation of women in top managerial levels will serve not only social and gender equality goals, but also organizational, business, and economic goals and performance. In partnership with 8400 we introduce a HealthTech launchpad program to promote junior women managers to executive positions throughout the ecosystem.